MedTrace Logo

Testosterone Treatment for Hypogonadal Men

NCT00433199 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 274

Last updated 2015-01-27

Study results available
· View outcomes & findings →

Summary

Demonstrate efficacy and safety of Testosterone Gel 1.62% for the treatment of hypogonadal men

Conditions

  • Hypogonadism

Interventions

DRUG

Testosterone (T) Gel 1.62%

Testosterone gel 1.62% contains 1.62% testosterone gel as active ingredient.

DRUG

Placebo

Placebo Control

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Director Solvay · Abbott Products

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2007-10-31
Completion
2008-04-30

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00433199 on ClinicalTrials.gov